The British Society for Rheumatology has updated its guideline for the management of gout and has recommended that urate-lowering drugs be offered to patients who are early in the progression of their disease, according to a press release.
“Guidelines are massively important. Rheumatologists, general medical consultants and general practitioners will all be interested in this one,” Elizabeth MacPhie, chair of the Standards, Audit and Guidelines Working Group for the British Society for Rheumatology, said in the release. “Gout is our most ‘in demand’ guideline. This is because gout is common, excruciatingly painful and certainly not confined to the 18th century, as the public might believe.”
Another key recommendation is for patients to be screened for cardiovascular risk factors and comorbid conditions, such as smoking status, hypertension, diabetes, dyslipidemia, obesity and renal disease.
For more information: